At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.

Employee Rating

3More
TypeSubsidiary
Parent CompanyThermo Fisher Scientific
HQDurham, US
Founded1974
Websitepatheon.com
Cybersecurity ratingDMore
Patheon was founded in 1974 and is headquartered in Durham, US

Viewing summary data as a guest

Sign up for free to see all data

Patheon Office Locations

Patheon has offices in Durham, Bend, Berkeley, Cincinnati and in 20 other locations
Durham, US (HQ)
4815 Emperor Blvd #300
Bend, US
62925 NE 18th St
Berkeley, US
4766 La Guardia Dr
Cincinnati, US
2110 E Galbraith Rd
Florence, US
6173 E Old Marion Hwy
Greenville, US
309 Delaware St
Show all (28)

Patheon Financials and Metrics

Summary Metrics

Founding Date

1974
Patheon is a subsidiary of Thermo Fisher Scientific

Patheon Revenue

Embed Graph
View revenue for all periods
Patheon's revenue was reported to be $1.02 b in FY, 2013
Annual
USDFY, 2012FY, 2013

Revenue

749.1m1.0b

Cost of goods sold

589.8m774.0m

Gross profit

159.3m249.1m

Gross profit Margin, %

21%24%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013

Revenue

153.9m181.5m203.7m213.5m253.9m265.7m

Cost of goods sold

139.5m147.5m148.2m171.1m196.9m194.6m

Gross profit

14.4m34.0m55.5m42.4m57.0m71.1m

Gross profit Margin, %

9%19%27%20%22%27%
Annual
USDFY, 2012FY, 2013

Cash

39.4m61.6m

Accounts Receivable

161.7m191.3m

Prepaid Expenses

11.9m15.3m

Inventories

82.3m137.8m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013

Cash

32.5m19.6m35.4m55.4m57.1m40.9m

Accounts Receivable

125.0m147.3m138.1m168.7m179.7m181.7m

Prepaid Expenses

12.8m12.5m16.3m11.4m13.4m21.7m

Inventories

83.0m86.9m90.3m141.7m139.9m144.3m
Annual
USDFY, 2012FY, 2013

Net Income

(106.7m)(35.7m)

Depreciation and Amortization

40.8m48.4m

Inventories

(2.7m)(800.0k)

Accounts Payable

5.3m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013

Net Income

(19.3m)(98.9m)(83.5m)(51.4m)(51.3m)(46.9m)

Depreciation and Amortization

10.6m21.4m30.8m11.0m23.2m35.6m

Cash From Operating Activities

9.9m(22.9m)6.8m(6.3m)(17.3m)(25.7m)

Purchases of PP&E

(6.5m)(17.6m)(32.9m)(8.4m)(18.5m)(34.2m)
USDQ1, 2012

Debt/Equity

1.4 x

Debt/Assets

0.4 x

Financial Leverage

3.8 x
Show all financial metrics

Patheon Cybersecurity Score

Cybersecurity ratingPremium dataset

D

64/100

SecurityScorecard logo

Patheon Online and Social Media Presence

Embed Graph

Patheon News and Updates

Thermo Fisher spotlights its problem-solvers in campaign aimed at pharma clients

​​​​​​​Thermo Fisher is showing its real face to pharma clients. Make that faces—those of its employees and the patients they help. In its new campaign, Thermo Fisher Scientific Pharma Services is looking to personalize its end-to-end drug development and delivery services for pharma companies.

Empty Capsules Market to Surpass US$ 2.79 Billion Threshold by 2025 Globally

Empty capsules market to surpass US$ 2.79 billion threshold by 2025 globally, with development of capsules integrated with advanced technologies such as extended release Posted via Industry Today. Follow us on Twitter @IndustryToday

Pharmaceutical Solid Dosage Contract Manufacturing Market to witness steady increase by 2024

The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday

Pharmaceutical Solid Dosage Contract Manufacturing Market: Industry Latest Trends & Global Outlook 2016-2024

The major factors that are driving the pharmaceutical solid dosage contract manufacturing market include lower and more flexible manufacturing, reduced net costs, streamlined development, and availability of the higher quality product. Posted via Industry Today. Follow us on Twitter @IndustryToday

Vicarius Pharma lands $21.8 mln

Switzerland-based Vicarius Pharma AG, which provides U.S.-based biopharmaceutical companies a "novel approach" to commercializing assets in European markets, has raised $21.8 million in funding. James Mullen, CEO of Patheon and former CEO of Biogen, was the lead investor.
Show more

Patheon Frequently Asked Questions

  • When was Patheon founded?

    Patheon was founded in 1974.

  • How many employees does Patheon have?

    Patheon has 3,104 employees.

  • What is Patheon revenue?

    Latest Patheon annual revenue is $1 b.

  • What is Patheon revenue per employee?

    Latest Patheon revenue per employee is $329.6 k.

  • Who are Patheon competitors?

    Competitors of Patheon include Precision Medicine Group, Principia BioPharma and Verona Pharma.

  • Where is Patheon headquarters?

    Patheon headquarters is located at 4815 Emperor Blvd #300, Durham.

  • Where are Patheon offices?

    Patheon has offices in Durham, Bend, Berkeley, Cincinnati and in 20 other locations.

  • How many offices does Patheon have?

    Patheon has 28 offices.